Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)-A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)-

被引：0
|
作者：
Park, Y.
Akabane, H.
Watanabe, T.
Takahashi, M.
Sagara, Y.
Nishimura, R.
Tsurutani, J.
Takashima, T.
Fujisawa, T.
Hozumi, Y.
Uemura, Y.
Mukai, H.
机构：
[1] Tohoku Med & Pharmaceut Univ, Fac Med, Sendai, Miyagi, Japan
[2] Hokkaido PWFAC Asahikawa Kosei Gen Hosp, Asahikawa, Hokkaido, Japan
[3] Sendai Med Ctr, Natl Hosp Org, Sendai, Miyagi, Japan
[4] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Hakuaikai Med Corp Sagara Hosp, Kagoshima, Japan
[6] Kumamoto Shinto Gen Hosp, Kumamoto, Japan
[7] Kindai Univ, Fac Med, Osakasayama, Japan
[8] Osaka City Univ, Grad Sch Med, Osaka, Japan
[9] Gunma Prefectural Canc Ctr, Ota, Japan
[10] Univ Tsukuba Hosp, Ibaraki Prefectural Cent Hosp, Kasama, Ibaraki, Japan
[11] Univ Tokyo Hosp, Tokyo, Japan
[12] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-14-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC)
    Nishimura, Reiki
    Mukai, Hirofumi
    Uemura, Yukari
    Akabane, Hiromitsu
    Park, Youngjin
    Takahashi, Masato
    Sagara, Yoshiaki
    Takashima, Tsutomu
    Fujisawa, Tomomi
    Hozumi, Yasuo
    Kawahara, Takuya
    Watanabe, Takanori
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).
    Hara, Fumikata
    Mukai, Hirofumi
    Ohsumi, Shozo
    Yotsumoto, Daisuke
    Takashima, Tsutomu
    Hozumi, Yasuo
    Watanabe, Takanori
    Saito, Tsuyoshi
    Watanabe, Ken-ichi
    Tsurutani, Junji
    Toyama, Tatsuya
    Akabane, Hiromitsu
    Nishimura, Reiki
    Taira, Naruto
    Uemura, Yukari
    Ohashi, Yasuo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Moth, Shigeru
    Takashima, Tsutomu
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Ohashi, Yasuo
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR-MBC01)
    Watanabe, Takanori
    Shimozuma, Kojiro
    Imi, Kentaro
    Doihara, Hiroyoshi
    Akabane, Hiromitsu
    Ueo, Hiroaki
    Ohno, Shinji
    Kashiwaba, Masahiro
    Fukuuchi, Atsushi
    Watanabe, Kenichi
    Tsuneizumi, Michiko
    Isaka, Hirotsugu
    Uemura, Yukari
    Ohashi, Yasuo
    Mukai, Hirofumi
    CANCER RESEARCH, 2015, 75
  • [5] Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
    Takeru Shiroiwa
    Takashi Fukuda
    Kojiro Shimozuma
    Mitsuko Mouri
    Yasuhiro Hagiwara
    Takuya Kawahara
    Shozo Ohsumi
    Yasuo Hozumi
    Yoshiaki Sagara
    Yasuo Ohashi
    Hirofumi Mukai
    BMC Cancer, 17
  • [6] Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
    Shiroiwa, Takeru
    Fukuda, Takashi
    Shimozuma, Kojiro
    Mouri, Mitsuko
    Hagiwara, Yasuhiro
    Kawahara, Takuya
    Ohsumi, Shozo
    Hozumi, Yasuo
    Sagara, Yoshiaki
    Ohashi, Yasuo
    Mukai, Hirofumi
    BMC CANCER, 2017, 17
  • [7] COST-EFFECTIVENESS OF FIRST-LINE S-1 THERAPY FOR METASTATIC BREAST CANCER PATIENTS COMPARED WITH TAXANES: AN ANALYSIS BASED ON THE RANDOMIZED PHASE III SELECT BC TRIAL
    Shiroiwa, T.
    Fukuda, T.
    Shimozuma, K.
    Mouri, M.
    Hagiwara, Y.
    Kawahara, T.
    Ohsumi, S.
    Hozumi, Y.
    Sagara, Y.
    Ohashi, Y.
    Mukai, H.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [8] Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
    Takashima, Tsutomu
    Mukai, Hirofumi
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Imoto, Shigeru
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Shimozuma, Kojiro
    Ohashi, Yasuo
    LANCET ONCOLOGY, 2016, 17 (01): : 90 - 98
  • [9] Randomized Study of Taxane Versus TS-1 in Women with Metastatic or Recurrent Breast Cancer (SELECT BC)
    Mukai, Hirofumi
    Takashima, Tsutomu
    Hozumi, Yasuo
    Watanabe, Takanori
    Murakami, Shigeru
    Masuda, Norikazu
    Mitsuyama, Shoshu
    Ohmura, Tousei
    Yajima, Tamiko
    Ohashi, Yasuo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 811 - 814
  • [10] Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer
    Hirofumi Mukai
    Yukari Uemura
    Hiromitsu Akabane
    Takanori Watanabe
    Youngjin Park
    Masato Takahashi
    Yoshiaki Sagara
    Reiki Nishimura
    Tsutomu Takashima
    Tomomi Fujisawa
    Yasuo Hozumi
    Takuya Kawahara
    British Journal of Cancer, 2021, 125 : 1217 - 1225
12345